<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10555756</article-id><article-id pub-id-type="pmc">2374290</article-id><article-id pub-id-type="pii">6690774</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690774</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kooten</surname><given-names>M Van</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Traine</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cinat</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cazap</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Comba</surname><given-names>A Zori</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Vicente</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Sena</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Nievas</surname><given-names>O Rodriguez</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Orlando</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Alexander Fleming Institute, Cramer 1180, Buenos Aires 1426, Argentina</aff><aff id="aff2"><label>2</label>Hospital Israelita, Buenos Aires, Argentina</aff><aff id="aff3"><label>3</label>Instituto Angel H Roffo, Buenos Aires, Argentina</aff><aff id="aff4"><label>4</label>Instituto Estevez, Buenos Aires, Argentina</aff><aff id="aff5"><label>5</label>Hospital Alem&#x000e1;n, Buenos Aires, Argentina</aff><aff id="aff6"><label>6</label>Hospital Zubizarrteta, Buenos Aires, Argentina</aff><aff id="aff7"><label>7</label>Hospital Torn&#x000fa;, Buenos Aires, Argentina</aff><aff id="aff8"><label>8</label>Centro Oncologico de Excelencia, Gonnet, Argentina</aff><aff id="aff9"><label>9</label>Hospital Durand, Buenos Aires, Argentina</aff><aff id="aff10"><label>10</label>Hospital Municipal de Oncologia Marie Curie, Buenos Aires, Argentina</aff><pub-date pub-type="ppub"><month>11</month><year>1999</year></pub-date><volume>81</volume><issue>5</issue><fpage>846</fpage><lpage>849</lpage><history><date date-type="received"><day>29</day><month>01</month><year>1999</year></date><date date-type="rev-recd"><day>10</day><month>05</month><year>1999</year></date><date date-type="accepted"><day>07</day><month>06</month><year>1999</year></date></history><copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The activity and mild toxicity profile of single-agent gemcitabine therapy in untreated (chemonaive) patients with non-small-cell lung cancer (NSCLC) is well documented. This phase II trial was conducted to determine the objective tumour response rate and toxicity profile of single-agent gemcitabine in pretreated patients with NSCLC. Patients with histological evidence of advanced NCSLC stage IIIB or IV; at least one prior chemotherapy regimen including a platinum or taxane analogue; an Eastern Cooperative Oncology Group (ECOG) performance status of 0&#x02013;2; clinically measurable disease; adequate bone marrow reserve; and adequate renal function; received 1000 mg m<sup>&#x02013;2</sup> gemcitabine administered over 30 min on days 1, 8 and 15 of a 28-day cycle defined as 3 weekly treatments followed by 1 week of rest. Twenty-nine patients were evaluated for efficacy and 32 for toxicity. One patient achieved a complete response and five patients had a partial response resulting in a total response rate of 20.6&#x00025; (95&#x00025; confidence interval (CI) 6&#x02013;34). Median response duration was 7 months (range 4&#x02013;11 months). Twelve (41&#x00025;) patients reached stable disease after two cycles of therapy and 11 (38&#x00025;) patients had disease progression. Median progression-free survival time was 3 months and median overall survival time was 5.5 months. Toxicity was generally mild (grades 0&#x02013;2). Severe (grade 3 or 4) haematological toxicities included grade 3 anaemia in one patient and grade 3 thrombocytopenia in two patients. Severe non-haematological toxicities included one patient each with grade 3 liver transaminase elevations, nausea/vomiting and diarrhoea. This study confirms the activity and safety of single-agent gemcitabine in pretreated patients with advanced NSCLC who are refractory or sensitive to first-line therapy. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>gemcitabine</kwd><kwd>advanced non-small-cell lung cancer</kwd><kwd>second-line chemotherapy</kwd></kwd-group></article-meta></front></article>


